RxDoctor Payments Data

Austin Prince

Physician Assistant · Oakdale, NYNPI 1821768557

Payments from drug & device makers

$2,392in general payments, 2019–2025

Across 106 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$532
  • Lilly USA, LLC$276
  • AstraZeneca$260
  • AbbVie$231
  • Pfizer$181
  • Abbott$141
  • plus $770 from 17 others

What the payments were for

  • Food & beverage$2,380100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,392 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$84,395
Medicare patients
198
Services billed
1,942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide46$79,412
OzempicSemaglutide41$62,923
RybelsusSemaglutide38$61,150
FarxigaDapagliflozin Propanediol38$50,232
EliquisApixaban21$32,782
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$19,315
BelsomraSuvorexant16$7,717
Bupropion XlBupropion Hcl37$4,410
Albuterol Sulfate HfaAlbuterol Sulfate34$1,001
Metoprolol Succinate46$1,000
Levothyroxine Sodium39$768
Sertraline Hcl23$581
Atorvastatin Calcium83$470
Rosuvastatin Calcium47$389
Cyclobenzaprine Hcl12$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$532$124,07279 claims
Lilly USA, LLCMounjaro$276$79,41246 claims
AstraZenecaFarxiga, Breztri Aerosphere$260$69,54760 claims
PfizerEliquis$181$32,78221 claims
MerckBelsomra$54$7,71716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Oakdale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →